1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
186.84 USD   -3.78%
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
08/05PUMP / DUMP #40 : This week's gainers and losers
MS
08/05U.S. administers over 7,300 Novavax vaccine doses - CDC
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna COVID-19 shots now an option for older kids in US

06/24/2022 | 11:18am EDT

NEW YORK (AP) — There is now a second COVID-19 option for kids ages 6 to 17 in the U.S.

The Centers for Disease Control and Prevention on Friday announced it is recommending Moderna shots as an option for school-age kids and teens. This group has been able to get shots made by Pfizer since last year.

CDC sets the federal government’s vaccine guidance for U.S. doctors and their patients.

Last week, the Food and Drug Administration authorized the shots — full-strength doses for children ages 12 to 17 and half-strength for those 6 to 11. The doses are to be given about a month apart. An expert advisory panel this week voted unanimously to recommend that CDC endorse the Moderna shots, too.

Moderna officials have said they expect to later offer a booster to all kids ages 6 to 17.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about MODERNA, INC.
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
08/05PUMP / DUMP #40 : This week's gainers and losers
MS
08/05U.S. administers over 7,300 Novavax vaccine doses - CDC
RE
08/04Goldman Sachs Raises Moderna's Price Target to $296 From $290, Maintains Buy Rating
MT
08/04Morgan Stanley Adjusts Moderna's Price Target to $197 From $199, Maintains Equalweight ..
MT
08/04SVB Securities Adjusts Moderna's Price Target to $74 from $77, Keeps Underperform Ratin..
MT
08/04MARKETSCREENER'S WORLD PRESS REVIEW : August 4, 2022
MS
08/04Moderna Reiterates $21 Billion COVID-19 Vaccine Sales Forecast On Expected New Approval..
MT
08/03US Stocks Advance on Surprise Increase in Service Activity, Rise in Factory Orders
MT
08/03Nasdaq ends at three-month high as PayPal fuels optimism
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 875 M - -
Net income 2022 11 063 M - -
Net cash 2022 17 049 M - -
P/E ratio 2022 7,03x
Yield 2022 -
Capitalization 73 092 M 73 092 M -
EV / Sales 2022 2,56x
EV / Sales 2023 5,16x
Nbr of Employees 2 700
Free-Float 92,1%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 186,84 $
Average target price 214,00 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235
CELLTRION, INC.-0.51%20 815